Safety of modified stem cell infusion with organ transplant
Part of Immune system & allergy clinical trials.
This early-phase trial tests whether it is safe to give a special type of stem cell transplant (with the naïve T cells removed and only memory T cells left) to people receiving organ transplants. It is for children getting intestine or lung transplants, and for children or adults getting kidney transplants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a child (under 18) needing a small intestine or lung transplant, or you are a child or adult needing a kidney transplant (or already had one and still need a stem cell transplant).
- You or your legal guardian must agree to the study and sign a consent form before any tests or treatments.
- You must not have any uncontrolled infections or serious medical problems that would make the combined transplant unsafe.
- You must not have a bone marrow disease or take medicines that harm your bone marrow.
- You must not have severe organ failure (like heart, liver, or lung problems) that would make the surgery too risky.
- Women who are pregnant or breastfeeding are not eligible.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
This trial tests whether a gentler (reduced-intensity) conditioning treatment before a stem cell transplant works for non-cancer diseases. It uses specific donor stem cell matches and checks heart, lung, liver, and kidney function to help lower transplant stress while still aiming for benefit.
This trial gives patients access to a special machine that cleans stem cells before they are transplanted, which may reduce the risk of graft-versus-host disease. It is for patients getting certain types of stem cell transplants or having poor graft function after a transplant.
This trial tests a stem cell transplant from a matched sibling donor, followed by extra immune cells to help prevent relapse in people with high-risk acute myeloid leukemia (AML) who are in remission. It aims to improve outcomes by boosting the immune system's ability to fight any remaining leukemia cells.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
Hear when a new Solid Organ Transplant Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.